Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains
- 1 July 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (7) , 2389-2394
- https://doi.org/10.1128/aac.01422-07
Abstract
Ceftobiprole (BPR) is an investigational cephalosporin with activity against Staphylococcus aureus , including methicillin-resistant S. aureus (MRSA) strains. The pharmacodynamic (PD) profile of BPR against S. aureus strains with a variety of susceptibility phenotypes in an immunocompromised murine pneumonia model was characterized. The BPR MICs of the test isolates ranged from 0.25 to 2 μg/ml. Pharmacokinetic (PK) studies were conducted with infected neutropenic BALB/c mice; and the BPR concentrations were measured in plasma, epithelial lining fluid (ELF), and lung tissue. PD studies with these mice were undertaken with eight S. aureus isolates (two methicillin-susceptible S. aureus strains, three hospital-acquired MRSA strains, and three community-acquired MRSA strains). Subcutaneous BPR doses of 2 to 125 mg/kg of body weight/day were administered, and the change in the number of log 10 CFU/ml in lungs was evaluated after 24 h of therapy. The PD profile was characterized by using the free drug exposures ( f ) determined from the following parameters: the percentage of time that the concentration was greater than the MIC ( T > MIC), the maximum concentration in serum/MIC, and the area under the concentration-time curve/MIC. The BPR PK parameters were linear over the dose range studied in plasma, and the ELF concentrations ranged from 60 to 94% of the free plasma concentration. fT > MIC was the parameter that best correlated with efficacy against a diverse array of S. aureus isolates in this murine pneumonia model. The 80% effective dose (ED 80 ), ED 50 , and stasis exposures appeared to be similar among the isolates studied. BPR exerted maximal antibacterial effects when fT > MIC ranged from 6 to 22%, regardless of the phenotypic profile of resistance to β-lactam, fluoroquinolone, erythromycin, clindamycin, or tetracycline antibiotics.Keywords
This publication has 30 references indexed in Scilit:
- Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacyExpert Opinion on Investigational Drugs, 2007
- Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumoniaDiagnostic Microbiology and Infectious Disease, 2006
- Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?Current Opinion in Infectious Diseases, 2006
- General informationJournal of the American Medical Directors Association, 2006
- Epidemiology, Treatment, and Prevention of Community-Acquired Methicillin-Resistant Staphylococcus aureus InfectionsMayo Clinic Proceedings, 2005
- A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid–liquid extraction and reversed-phase HPLCJournal of Pharmaceutical and Biomedical Analysis, 2005
- Methicillin-ResistantStaphylococcus aureusDisease in Three CommunitiesNew England Journal of Medicine, 2005
- Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesDiagnostic Microbiology and Infectious Disease, 2004
- Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal PneumoniaAntimicrobial Agents and Chemotherapy, 2004
- Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcus pneumoniae in the Thigh Infection ModelAntimicrobial Agents and Chemotherapy, 2003